Serina Therapeutics, Inc. (SER) is a publicly traded Healthcare sector company. As of May 21, 2026, SER trades at $1.71 with a market cap of $22.65M and a P/E ratio of -0.90. SER moved +5.59% today. Year to date, SER is -18.27%; over the trailing twelve months it is -70.23%. Its 52-week range spans $1.22 to $8.14. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces SER's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Serina Therapeutics Secures $21.2M Financing, Advances SER-252 Phase 1b Parkinson’s Trial: Serina Therapeutics has initiated its Phase 1b registrational study of SER-252 in advanced Parkinson’s disease, expecting to complete Cohort 1 dosing by Q3 2026 and report single-ascending-dose data in H1 2027. The company closed a $21.2 million private placement, bolstering its cash to $24.5 million as of March 31, 2026.
| Metric | Value |
|---|---|
| Price | $1.71 |
| Market Cap | $22.65M |
| P/E Ratio | -0.90 |
| EPS | $-1.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.14 |
| 52-Week Low | $1.22 |
| Volume | 91 |
| Avg Volume | 0 |
| Revenue (TTM) | $130.00K |
| Net Income | $-19.21M |
| Gross Margin | 0.00% |
1 analysts cover SER: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.